prev next front |1 |2 |3 |4 |5 |6 |7 |8 |9 |10 |11 |12 |13 |14 |15 |16 |17 |18 |19 |20 |21 |22 |23 |review
Fig. 1. Schematic representation of AACs and aminoglycosides used in this study. All AACs were prepared as acetate salts. (A) NeoR6,hexa-arginine–neomycin conjugate; NeoR1, a 1:1 mixture of two mono-arginine–neomycin conjugates; NeoR2, a di-arginine–neomycin conjugate; NeamR1, a mono-arginine–neamine conjugate; NeamR4, a tetra-arginine–neamine conjugate; ParomR1, a mono-arginine–paromomycin conjugate; and ParomR5, a penta-arginine–paromomycin conjugate. (B) R3G, a tri-arginine–gentamycin C1 conjugate.